Literature DB >> 16688394

Utility of biochemical screening in the context of evaluating patients with a presumptive diagnosis of osteoporosis.

C Rajeswaran1, J Spencer, J H Barth, S M Orme.   

Abstract

The ageing population is expected to increase the burden of osteoporosis on the health care system. Secondary causes of osteoporosis are found in a proportion of patients. There is much controversy regarding the best work-up for patients who have been diagnosed as having osteoporosis based on bone mineral density. It is difficult to decide where interventions should be targeted both from a patient's perspective and for cost effectiveness. We evaluated the utility of a standard panel (full blood count, plasma viscosity, plasma protein, electrophoresis, urine Bence Jones protein, thyroid function test, bone profile, fasting lipids and liver function test) of biochemical investigations in 327 consecutive patients (287 females, 40 males) referred to the new patient osteoporosis clinic from April 1999 to March 2000. Patients were characterised after measurement of spinal/femoral neck bone mineral density after a dual energy X-ray absorptiometry (DEXA) scan. There were 88 patients with osteoporosis, 91 with osteopenia, 130 had normal bone mineral density and 20 who did not have a bone scan. No case of multiple myeloma was found in this cohort of patients. There was no difference in the mean plasma viscosity of patients with and without osteoporosis (P=0.182). There was no significant difference in the abnormal urine calcium/creatinine (Ca/Cr ratio) in patients with osteoporosis and those without osteoporosis (P=0.316). There was no significant difference in the prevalence of hypothyroidism (P=0.213) or thyrotoxicosis (P=0.138) in patients with and without osteoporosis. There was no strong correlation between cholesterol concentrations and osteoporosis (r=0.069). We found no utility in performing a myeloma screen. A small proportion of patients had abnormalities of calcium homeostasis or thyroid disease. We recommend that a screening biochemical evaluation should be restricted to calcium/bone profile and thyroid function tests in patients with a presumptive diagnosis of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16688394     DOI: 10.1007/s10067-006-0320-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

Review 1.  Laboratory workup for osteoporosis. Which tests are most cost-effective?

Authors:  Carolyn Crandall
Journal:  Postgrad Med       Date:  2003-09       Impact factor: 3.840

2.  Prevalence of low femoral bone density in older U.S. adults from NHANES III.

Authors:  A C Looker; E S Orwoll; C C Johnston; R L Lindsay; H W Wahner; W L Dunn; M S Calvo; T B Harris; S P Heyse
Journal:  J Bone Miner Res       Date:  1997-11       Impact factor: 6.741

3.  Does serum cholesterol contribute to vertebral bone loss in postmenopausal women?

Authors:  L B Tankó; Y Z Bagger; S B Nielsen; C Christiansen
Journal:  Bone       Date:  2003-01       Impact factor: 4.398

4.  The effectiveness of blood tests in detecting secondary osteoporosis or mimicking conditions in postmenopausal women.

Authors:  Alun Cooper; Sarah Brew; Simon de Lusignan
Journal:  Br J Gen Pract       Date:  2002-04       Impact factor: 5.386

5.  Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers.

Authors:  R D Harvey; K C McHardy; I W Reid; F Paterson; P D Bewsher; A Duncan; S P Robins
Journal:  J Clin Endocrinol Metab       Date:  1991-06       Impact factor: 5.958

Review 6.  Osteoporosis in men.

Authors:  A C Scane; A M Sutcliffe; R M Francis
Journal:  Baillieres Clin Rheumatol       Date:  1993-10

7.  Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham Osteoporosis Study.

Authors:  Elizabeth J Samelson; L Adrienne Cupples; Marian T Hannan; Peter W F Wilson; Setareh A Williams; Viola Vaccarino; Yuqing Zhang; Douglas P Kiel
Journal:  Bone       Date:  2004-03       Impact factor: 4.398

8.  Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women.

Authors:  Cara Tannenbaum; Julie Clark; Kevin Schwartzman; Sylvan Wallenstein; Robert Lapinski; Diane Meier; Marjorie Luckey
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

9.  Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.

Authors:  Lars Rejnmark; Niels Henrik Buus; Peter Vestergaard; Lene Heickendorff; Frederik Andreasen; Mogens Lytken Larsen; Leif Mosekilde
Journal:  J Bone Miner Res       Date:  2004-02-16       Impact factor: 6.741

Review 10.  Osteoporosis in men.

Authors:  E S Orwoll
Journal:  Endocrinol Metab Clin North Am       Date:  1998-06       Impact factor: 4.741

View more
  4 in total

1.  The utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis.

Authors:  F E McKiernan; R L Berg; J G Linneman
Journal:  Osteoporos Int       Date:  2010-06-09       Impact factor: 4.507

2.  Evaluation of Relationship Between SOD1 50-bp Deletion Gene Polymorphism, Cu, Zn Level, and Viscosity in Postmenopausal Osteoporosis Patients with Vertebral Fractures.

Authors:  Ahu Soyocak; Fulya Doganer; Dilek Duzgun Ergun; Metin Budak; Didem Turgut Coşan; Merih Ozgen
Journal:  Biol Trace Elem Res       Date:  2022-03-03       Impact factor: 3.738

3.  The value of laboratory tests in diagnosing secondary osteoporosis at a fracture and osteoporosis outpatient clinic.

Authors:  Gijs de Klerk; J Han Hegeman; Detlef van der Velde; Job van der Palen; Leo van Bergeijk; Henk J Ten Duis
Journal:  Geriatr Orthop Surg Rehabil       Date:  2013-06

4.  Early Detection of Osteoporosis by Dual Energy X-ray Absorptiometry.

Authors:  Asadullah Makhdoom; Makhdoom Rahopoto; Khaleeque Ahmed Siddiqui; Ghulam Ali Qureshi
Journal:  Pak J Med Sci       Date:  2014 Nov-Dec       Impact factor: 1.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.